| DIRECT COMPETITOR COMPARISON | |
| DYAX | ISPH | Pvt1 | VPHM | Industry | | Market Cap: | 316.09M | 448.54M | N/A | 589.33M | 100.26M | | Employees: | 164 | 250 | N/A | 201 | 68 | | Qtrly Rev Growth (yoy): | -17.90% | 26.10% | N/A | 22.20% | 19.70% | | Revenue (ttm): | 46.77M | 81.41M | N/A | 272.63M | 14.01M | | Gross Margin (ttm): | -15.93% | 25.35% | N/A | 91.39% | 65.67% | | EBITDA (ttm): | -30.43M | -39.53M | N/A | 95.85M | -12.30M | | Oper Margins (ttm): | -71.39% | -52.02% | N/A | 24.71% | -149.46% | | Net Income (ttm): | -45.08M | -47.12M | N/A | -21.75M | N/A | | EPS (ttm): | -0.687 | -0.781 | N/A | -0.271 | -0.33 | | P/E (ttm): | N/A | N/A | N/A | N/A | 16.37 | | PEG (5 yr expected): | N/A | N/A | N/A | N/A | 1.31 | | P/S (ttm): | 6.81 | 5.03 | N/A | 2.13 | 9.35 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.51 | 0.02% | 57.20B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.07 | 0.32% | 13.61B | 15.75 | | Genzyme Corp. | GENZ | 51.00 | -0.14% | 13.53B | 29.08 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.19 | -0.79% | 41.57B | 17.86 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.61 | -0.68% | 8.85B | 1012.45 | | Teva Pharmaceutical Industries Limited | TEVA | 52.76 | -0.23% | 46.48B | 48.27 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.33 | 1.00% | 3.96B | 19.24 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.81 | -1.17% | 2.93B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.93 | -0.44% | 5.48B | 110.00 | | Pfizer Inc. | PFE | 18.30 | 0.27% | 147.67B | 15.20 | | Johnson & Johnson | JNJ | 62.501 | -0.62% | 172.45B | 13.65 | | GlaxoSmithKline plc | GSK | 41.21 | -2.48% | 104.47B | 13.08 | | Sanofi-Aventis | SNY | 37.7781 | -1.70% | 98.64B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.3789 | -0.00% | 125.78B | 16.58 | | RHHBY.PK | 40.81 | -1.57% | N/A | N/A | | AstraZeneca plc | AZN | 44.62 | -1.48% | 64.70B | 8.96 | | Abbott Laboratories | ABT | 54.15 | 0.13% | 83.76B | 14.67 | | Bristol-Myers Squibb Co. | BMY | 25.39 | 0.04% | 50.30B | 13.14 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | ISPH | | Research Firm Lays Out Surprise Bio Events for 2010: BioBuzz
Mon 11:16am -
at TheStreet.com | | • | VPHM | | Biotech Bargains for Your Portfolio
Fri, Nov 27 -
at Motley Fool | | • | ISPH | | Inspire Announces Webcast of Presentation at Piper Jaffray Health Care Conference
Wed, Nov 25 -
Business Wire | | • | ISPH | | INSPIRE PHARMACEUTICALS INC Financials
Fri, Nov 13 -
EDGAR Online Financials | | • | ISPH | | Local stocks rise as Wall Street surges
Mon, Nov 9 -
at bizjournals.com | | • | ISPH | | Zacks Bull and Bear of the Day Highlights: Inspire Pharmaceuticals, Inc., Sears Holdings, Moody's Corp., CBS Corporation and Forest Oil Corporation
Mon, Nov 9 -
Zacks.com | | • | ISPH | | Inspire Pharmaceuticals, Inc. (ISPH)
Mon, Nov 9 -
Zacks.com | | • | ISPH | | New Star Analyst Rankings for Inspire Pharmaceuticals, Inc.
Sun, Nov 8 -
StarMine | | • | VPHM | | 7 Highly Rated Stocks on Sale
Wed, Nov 4 -
at Motley Fool | | • | VPHM | | VIROPHARMA INC Financials
Tue, Nov 3 -
EDGAR Online Financials | | • | VPHM | | ViroPharma to Present at Three November Healthcare Conferences
Thu, Oct 29 -
PR Newswire | | • | VPHM | | Drink In These 5 Top Stocks
Thu, Oct 29 -
at Motley Fool | | | All Headlines for these symbols... |
|
|
|
0.33% Nasdaq 
Competitors
